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Background: Echocardiographic optimization of pacemaker settings is the current standard of care for patients
treated with cardiac resynchronization therapy. However, the process requires considerable time of expert staff.
The BRAVO study is a non-inferiority trial comparing echocardiographic optimization of atrioventricular (AV) and
interventricular (VV) delay with an alternative method using non-invasive blood pressure monitoring that can be
automated to consume less staff resources.
Methods/Design: BRAVO is a multi-centre, randomized, cross-over, non-inferiority trial of 400 patients with a
previously implanted cardiac resynchronization device. Patients are randomly allocated to six months in each arm.
In the echocardiographic arm, AV delay is optimized using the iterative method and VV delay by maximizing LVOT
VTI. In the haemodynamic arm AV and VV delay are optimized using non-invasive blood pressure measured using
finger photoplethysmography. At the end of each six month arm, patients undergo the primary outcome measure of
objective exercise capacity, quantified as peak oxygen uptake (VO2) on a cardiopulmonary exercise test. Secondary
outcome measures are echocardiographic measurement of left ventricular remodelling, quality of life score and
N-terminal pro B-type Natriuretic Peptide (NT-pro BNP). The study is scheduled to complete recruitment in December
2013 and to complete follow up in December 2014.
Discussion: If exercise capacity is non-inferior with haemodynamic optimization compared with echocardiographic
optimization, it would be proof of concept that haemodynamic optimization is an acceptable alternative which has the
potential to be more easily implemented.
Trial registration: Clinicaltrials.gov NCT01258829
Keywords: Heart failure, Cardiac resynchronization therapy, OptimizationBackground
Onset of biventricular pacing results in immediate
improvements in cardiac function which is manifest as an
improvement in haemodynamic parameters [1-3] including
increased peak rate of rise of intraventricular pressure, [4]
an increase in stroke volume [5], and higher systemic
arterial blood pressure [4,6]. Longer-term effects
include improvements in clinical outcome measures* Correspondence: z.whinnett@imperial.ac.uk
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unless otherwise stated.including exercise capacity, reductions in LV volumes,
quality of life measures [7-9] and NT-pro BNP [10]. Over
even longer time frames, biventricular pacing has been
shown to reduce hospitalizations and mortality [11,12].
Although the precise mechanism of clinical benefit from
biventricular pacing is not yet adequately established, it is
clear that it can only affect cardiac function by changing
the timing of the electrical signals initiating cardiac
contraction. Just as switching on and off CRT creates
immediate haemodynamic effects, so does changing
the AV and VV timings [1,2,13]. Since the benefits
must come from the change in timings, it might matter
what timings are programmed.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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dynamic measurements vary between patients, perhaps
because of the complexity of the disease which has
many elements present in varying degrees in different
individuals, and also perhaps because of anatomical
variations in lead position [1,14-16].
Tailoring biventricular pacing therapy to an individual
by optimizing the AV and VV delay settings of the
device has long been considered a mechanistically
plausible way to maximise its clinical benefit. AV
delay optimization was performed in the landmark
studies of biventricular pacing [11,12].
In clinical practice, however, many patients do not
undergo the recommended echocardiographic optimization
process because of the lack of availability of skilled staff
time. This may explain why the uptake of optimization is
low; in one survey only 45% of patients received AV delay
optimization [17]. Uptake is likely to remain low until a
more technically convenient method is available. It is
difficult for the echocardiographic method to be automated
because it requires an operator to keep the probe still while
different settings are tested, and professional judgement is
needed to decide upon the preferred patterns. Blood
pressure has the advantage over Doppler velocity of being
able to undergo numerous replicate measurements
without skilled operators making the measurements. We
have reported on methods for conducting pressure-based
optimization which produces an unambiguous optimum,
is reproducible, can be automated, and recommends
biologically plausible values [14,18,19].
Design of echocardiographic protocol
In the CARE-HF study AV delay was optimized using
Doppler echocardiography of trans-mitral flow using the
iterative method [20]. The AV delay which was found to
provide maximum separation of the E and A waves was
programmed. This method for AV delay optimization is
often recommended in guidelines [21]. Estimation of
stroke volume using echocardiography, is recommended
as the method of choice for performing VV optimization
in guidelines for echocardiographic optimization [21].
Design of haemodynamic protocol
Outside the heart, the most readily observable effects of
changes in efficacy of CRT are changes in pressure and
flow. Of these pressure is more straightforward to measure
non-invasively with automatic equipment.
We have previously demonstrated that changing AV
delay has a larger effect on haemodynamics than changing
VV delay and results in a curvilinear acute blood pressure
response, which fits closely to a parabola [22]. A superior
signal to noise ratio is seen when this is performed at
higher heart rates [14]. Of the components of blood
pressure, systolic blood pressure appears to be the mostinformative and reproducible when used for AV delay
optimization [18]. The algorithm requires multiple
alternations between a tested and reference delay and
comparisons are made immediately before and after the
change [23]. This method is amenable to performing large
numbers of replicates, which narrows the confidence
interval of the estimated optimum [24]. We have found
that it is possible to closely predict the exercise optimum
from resting measurements by pacing at different heart
rates [25]. Very recently we showed how this could be
done with an appropriately transformed signal from a
pulse oximeter [26].
In BRAVO (British randomised controlled trial of
AV and VV optimization) we adopted a standardised
protocol based on our previous reports, which we
describe in the methods below. In principle, it could be
carried out with invasive pressure or with non-invasive
pressure or pulse oximetry recorded beat-to-beat with any
appropriate sensor.
The BRAVO study was set up with the aim of
determining whether optimization using non-invasive
haemodynamics is a possible clinical alternative to the
recommended echocardiographic optimization. If the
clinical outcomes are equivalent, this method would offer
important logistical advantages over echocardiography
as it can be operated by a single operator, could be
automated, causes minimal discomfort to the patient,
and the technology could be developed to become
integral to new CRT devices. BRAVO is designed as a
non-inferiority study with the primary endpoint of
objective exercise capacity measured using peak oxygen
uptake (peak VO2). Secondary endpoints are symptoms,
ventricular volumes, and NT-proBNP.
Study design
Patients will be recruited from 20 centres in the United
Kingdom. The trial has a crossover design. Patients are
randomly allocated to have the settings of their device
optimized using one method for six months and then
the other for six months.
A flow chart outlining the study design is provided in
Figure 1. At the screening visit, the inclusion and exclusion
criteria are checked and informed consent is obtained from
those who meet the criteria for entry.
Patients are then randomized. Each patient then
undergoes optimization according to their randomized
arm. Patients in sinus rhythm have both AV and VV
optimization performed. Patients in atrial fibrillation
undergo VV optimization only. Rate adaptive AV delay
functions are not activated during the study.
After 6 months patients attend for assessment including
the primary and secondary endpoints of cardiopulmonary
exercise, echocardiographic assessment of LV volumes,
QOL questionnaire, and NT-pro BNP. They then crossover
Figure 1 Flowchart of study design. Patients visit 4 times and undergo 2 AV/VV delay optimizations according to the echocardiographic and
finometer protocols.
Whinnett et al. BMC Cardiovascular Disorders 2014, 14:42 Page 3 of 9
http://www.biomedcentral.com/1471-2261/14/42to the other form of optimization, and have their
pacemaker set to this programming for the next six
months. After six months in the second arm, they attend
again for assessment of the endpoints. They have now
completed the study. Those patients who have a
preference for one of the two sets of settings will have the
device programmed according to their preference. For the
remainder, we will programme the pacemakers according
to the preference of their primary cardiologist.
The study design is Prospective, Randomized, and
Open with Blinded evaluation of Endpoints (PROBE).
The analysis of the cardiopulmonary exercise test data,
echocardiography, and blood results are performed by
investigators blinded to the study arm.
Inclusion and exclusion criteria
Study inclusion and exclusion criteria are shown in Table 1.
Patients must have a previous diagnosis of symptomatic
chronic heart failure and have been implanted with a
biventricular pacemaker or biventricular defibrillator
device. The device must have been implanted at least sixmonths prior to enrolment, because cardiac reverse
remodelling is known to occur after implantation and one
of the secondary outcome measures is left ventricular
volumes. We wanted to minimize the potential for any
differential effect on remodelling of the two optimization
schemes to be interfered with by effects arising from recent
implantation of the device.
Since the primary endpoint is peak VO2 measured
using a treadmill cardiopulmonary exercise test, ability
and willingness to walk on a treadmill is an inclusion
criterion.
Endpoints
The endpoints of BRAVO are designed to assess physio-
logical markers which are consistently reported to
improve following CRT implantation. The rationale
for this is that if these markers are less favourable
with haemodynamic optimization than with standard
echocardiographic optimization, then there would be
good reason to reject the use of this haemodynamic
optimization since it is biologically implausible that
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
A previous diagnosis of chronic heart failure Major cardiovascular event within 6 weeks prior to enrolment
Cardiac Resynchronisation Therapy Device (CRT) implanted at least
six months prior to enrolment.
Uncontrolled hypertension
A history of symptomatic congestive heart failure (NYHA Class II to IV). Participation in any other clinical trial which would conflict with this trial
At any time in the past, an ejection fraction <40% or documented
moderate to severely impaired systolic dysfunction.
Any condition that will preclude them from walking on a treadmill
adequately or participating fully in the study
Stable medical therapy for heart failure
The patient is willing, able, and committed to participate in the study
for the full length of the follow-up.
>90% biventricular pacing at entry
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physiological markers were worse.Primary endpoint
The primary endpoint is objective exercise capacity defined
as peak VO2 on cardiopulmonary exercise testing [27].
Peak VO2 measures a physical capacity that integrates
many elements and has strong prognostic value in heart
failure [28] Reproducibility of repeated measurements
of peak VO2 at separate hospital visits is well defined
[29] and measurement variability is sufficiently low
to allow it to be a suitable measure for assessing the
impact of optimization of CRT device settings on
exercise capacity without requiring an excessively large
study population.Secondary endpoints
Secondary outcome measures are left ventricular reverse
remodelling, quality of life score and N-terminal pro B-type
Natriuretic Peptide (NT-pro BNP). Left ventricular end
diastolic volume (LVEDV) is measured by echocardiography
and has been reported to decrease after implantation of
CRT devices [30].
Quality of life is assessed using standardised scores for
heart failure: SF-36v2 [31] and Minnesota living with
heart failure score [32].
The third secondary endpoint is NT-pro BNP.
Neuroendocrine activation may be both a marker of
and a mechanism for progressive deterioration in cardiac
function [10,33].Study conduct and regulatory issues
This study is conducted in compliance with Good Clinical
Practice (GCP) guidelines, consistent with the most recent
version of the Declaration of Helsinki. The study has
been approved by the South West London Research
Ethics Committee (3) and site specific assessments
were performed for each participating hospital.Clinical testing centres
While patients are recruited from many different hospitals,
all study visits are performed at one of two testing centres.
The two testing centres are Aberdeen Royal Infirmary and
Imperial College London. The advantage of this approach
is that the equipment for making clinical measurements is
kept constant during the study. It also facilitates training of
staff performing the study in order to keep study costs to a
minimum.
Measurements
Baseline measurements
All recruited patients undergo a baseline physical
examination, medical history questionnaire, 12 lead ECG
including a documentation of the underlying rhythm
where possible, anthropometrics, blood samples are taken
and QoL score documented as described below.
AV and VV delay optimization
Patients in sinus rhythm have the following AV delays
tested unless the rhythm becomes intrinsic at a shorter
AV delay: 40, 80, 120, 160, 200, 240, 280, and 320 ms.
Some devices do not permit 240 and 280 ms: in which
case 250 and 275 ms are used instead.
Tested VV delays are LV first by 80 ms, 60 ms, 40 ms,
20 ms, 0 ms, and RV first by 20 ms, 40 ms, 60 ms and
80 ms. In devices that do not allow programming of
these values, the nearest permitted value is used.
Non-invasive haemodynamic optimization protocol
Beat-to-beat blood pressure is measured non-invasively
using the Finometer device (Finapres Medical Systems,
Netherlands). This digital photoplethysmograph uses an
inflatable finger cuff and applies a volume-clamp technique
[34] to yield a continuous arterial pressure waveform. This
technique has been extensively validated for measuring
changes in blood pressure [35-38].
The data is read into a custom data acquisition system.
In brief, this consists of an analogue-to-digital card
(DAQCard-6062E, National Instruments, Austin, TX,
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in the Labview instrument control language (v7.0,
National Instruments, Austin, TX, USA). Data is analysed
off-line using custom-written software [39-41] based
largely on Matlab (Natick, MA, USA), which has been
developed, and validated at the lead centre [41-43].
When using a physiological variable in order to guide
the optimization of CRT settings it is important that
enough steps are taken to minimize the effects of
biologic variability. Without these steps noise is likely
to overwhelm the signal and the results obtained are
unlikely to be reliable [44,45].
In this study we use a protocol designed to minimise
the effect of noise, this has been described in detail
previously but in brief consists of the following steps
[14,22,23,25]. Each tested delay is compared to a reference
delay (for AV delay 120 ms, for VV delay 0 ms) and the
relative change in acute blood systolic blood pressure
is calculated as the difference of the mean of 8 beats
immediately before the transition to the tested delayFigure 2 Calculating the relative change in systolic blood pressure (S
(AVD) of 120 ms and a tested AVD of 40 ms. Eight beats from the cont
(top picture), this process is repeated to include a minimum of 6 transition
AVD (lower picture) is an average of the change in systolic blood pressurecompared to the mean of the 8 beats immediately
after the transition. For each tested delay multiple
transitions between the tested and reference delays
(a minimum of six transitions) are made and the
mean relative change in acute systolic blood pressure
is calculated (Figure 2).
The optimal AV or VV delay is identified as the
peak of a fitted curve [22] unless the longest tested
delay results in the greatest increase in pressure, in
which case this is taken as the optimal value since fitting a
curve in this case will result in a non-physiological AV
delay being reported as optimal.
In order to maximize signal-to-noise ratio, optimization
is performed during atrial pacing with an elevated
heart rate (40 bpm above the resting heart rate if
paced or 45 bpm if sensed). This identified optimum
is programmed as the paced AV delay. The sensed AV
delay for haemodynamic optima is programmed to be
60 ms shorter based on data previously acquired with this
protocol.ys BPrel (mmHg) between a reference atrio-ventricular delay
inuous arterial pressure waveform are averaged from each AVD
s for each AVD tested (middle picture). SBPrel plotted against the
(8-beat average).
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AV optimization is performed by assessing the pattern of
pulsed wave Doppler recorded through the mitral valve
using the iterative method (Figure 3) [11]. Doppler data is
acquired using a GE Vivid-I machine (GE Healthcare).
Delays which produce intrinsic ventricular conduction
are excluded from analysis. The AV delay with the
best filling pattern, defined using the published protocol
from CARE-HF, [11] is programmed as the sensed
AV delay. The paced AV delay is programmed as
30 ms longer than the optimal sensed AV delay as per
recent guidelines [21].
VV optimization is performed after AV delay op-
timization. The AV delay is set to the value determined
as optimal during the AV delay optimization during VV
optimization. The VV delay yielding the highest mean
LVOT VTI, determined from 5 beats, is selected as the
optimal VV delay.
Endpoint measurements
Cardiopulmonary exercise testing
Patients exercise on a treadmill using a “smoothed
modified Bruce” protocol [46]. Spirometry and gas
exchange are monitored using the COSMED Quark CPX
System (COSMED S.r.l. Rome, Italy) or an Medisoft
Ergocard ++ unit (Medisoft group, Sorrines, Belgium),
Exercise capacity is measured as peak VO2 in ml/kg/min.
VE/VCO2 slope and oxygen uptake efficiency slope are
also measured [29].
Echocardiography
Additional echocardiographic measurements are made
using a Philips ie33 machine (Philips, Netherlands) usingFigure 3 Echocardiographic optimization of atrio-ventricular delay (Aan S5-1 probe with the patient semi recumbent in the left
lateral position. For each parameter the mean of three
measurements are calculated, the following parameters
are measured: left ventricular dimensions, volumes and
ejection fraction from the four and 2 chamber views,
quantification of mitral regurgitation and maximum
velocity through the aortic valve. Tissue Doppler imaging
(TDI) is used to measure longitudinal function at the
mitral valve annulus level on the lateral, septal, and
inferior walls. Where image quality is suitable a 3D
dataset is obtained using an X3-1 probe and used for
off-line calculation of volumes and ejection fraction
by a physiologist blinded to the study arm.
Quality of life questionnaire
Quality of life (QoL) is scored using the Minnesota
Living with Heart Failure Questionnaire (MLHFQ)
(http://www.mlhfq.org/) [32] and SF-36 [31] (http://
www.sf-36.org/tools/sf36.shtml). The MLHFQ question-
naire is a validated condition-specific measure with good
sensitivity and discrimination. It will be complemented
with the SF-36, a validated generic measure of QoL,
which enables comparison of findings with other outcome
studies.
Blood samples
Blood samples are taken for analysis of N-terminal
pro-B-type Natriuretic Peptide (NT-pro BNP).
Sub-studies
In a subset of patients reproducibility of cardiopulmo-
nary exercise testing is investigated by conducting a
second exercise test, within a two week period, prior toVD) using the iterative method. Abbreviations E wave, A wave.
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performed to assess the reproducibility of the two
optimization protocols. In a further subgroup the
impact of AV delay on longer term blood pressure is
assessed by 24 hour ambulatory blood pressure measure-
ment. This is carried out, following optimization, at the
initial visit (time of randomization) and again at 6 month
follow- up.
Statistics
Distributions will be described by the mean and standard
deviation, where they meet criteria for normality. Skewed
data will be appropriately transformed prior to analysis.
Analysis of the cross-over data will be performed using
linear mixed effects models [47]. Sample size calculations
were carried out using nQuery Advisor and are given in
detail in the section below.
Sample size calculations
All sample size calculations were based on paired t-tests
comparing outcomes for echocardiographic optimization
versus haemodynamic optimization.
The reproducibility of peak VO2 in heart failure
patients between two separate visits using a smoothed
modified Bruce protocol on a standard treadmill is
2.4 ml/kg/min, expressed as standard deviation of
difference between two independent measurements
[48]. Implantation of a CRT pacemaker results in a
0.5-2.5 (mean 1.5) ml/kg/min increase in peak VO2
[8,9,49-53]. Simply implanting a CRT device yields a
haemodynamic improvement of 5–6 mmHg of systolic
blood pressure [11,12]. Optimizing the settings after
implantation appears in preliminary work to add a further
3-6 mmHg increase in pressure, [1] i.e. between 50-100%
of the effect of CRT.
The study sample size was chosen to have 90% power
to detect a margin of equivalence of 0.75 ml/kg/min at
the 5% significance level. This is the smallest difference
between the treatment mean and the reference mean
that still results in the conclusion of non-inferiority and
corresponds to half the expected clinically meaningful
difference as advocated by Jones et al. [54] using a one
sided t-test of equivalence in means. On this basis 338
patients (N1 = 177/N2 = 177) are required. Mean mortality
and dropout in similar populations over a 12-month
period has been observed to be between 10% and 15%. In
order to accommodate possible losses to follow-up as high
as this, the target enrolment is 400 patients.
Left ventricular end-diastolic volume
The standard deviation of the difference of LV end-diastolic
volume measurements has previously been reported as
23.8 ml [55]. Following CRT reductions in LV end-diastolic
volumes are variable but of the order of 25 ml [56] On thisbasis 338 patients provides >99% power to detect a margin
of equivalence of 12.5 ml (50% of clinically significant
difference), and permits a difference of 7.4 ml to be
detected with 90% power at a significance level of 5%.
Quality of life and NT-pro BNP
For SF-36, the standard deviation of the difference of
scores has previously been reported to be 26 [17].
Previous studies of CRT have reported improvements
of ~17. With 338 patients we have 92% power to detect a
margin of equivalence of 8.5 at a significance level of 5%.
For the Minnesota questionnaire, mild improvements in
QoL are represented by a change of 12 with a typical
standard deviation of 15 [48]. With 338 patients we
would be able to easily detect a mild improvement of this
magnitude (>99% power) and have 90% power to detect
an equivalence limit of 4 points in the Minnesota score.
For NT-proBNP, CARE-HF reported median reductions
of 656 pg/ml in NT-pro BNP (adjusted for change in
control group) [10]. The within subject coefficient of
variation (σw/mean) in log NT-proBNP levels in people
with chronic heart failure over 12 months has been
reported to be ~10%, i.e. around 190 pg/ml [57].
Assuming a log normal distribution of NT-proBNP,
with 338 patients we will be able to easily detect an
equivalence limit of half the clinically reported difference
with >99% power at 5% significance level and have
90% power to detect an equivalence limit of 0.062 log
units (i.e. a fall in baseline NT-pro BNP from 1900 pg/ml
to 1647 pg/ml) at a 5% significance level.
Adverse events
All adverse events will be documented. Serious adverse
events are defined as those which are not anticipated
or not known to be related to the condition being
studied or the intervention being used that would
result in any of the following outcomes: death, life-
threatening condition, unexpected/unplanned in-patient
hospitalisation, persistent or significant disability or
incapacity, is a congenital anomaly or birth defect.
Timelines
The first patient was randomised in December 2010.
Recruitment is expected to be complete by December
2013. The study will report in 2015 after follow up of
all participants is complete.
Discussion
If exercise capacity is non-inferior with haemodynamic
optimization compared with echocardiographic optimi-
zation, it would be proof of concept that haemodynamic
optimization is an acceptable alternative which has the
potential to be more easily implemented. We already
know that it is much more capable of being automated,
Whinnett et al. BMC Cardiovascular Disorders 2014, 14:42 Page 8 of 9
http://www.biomedcentral.com/1471-2261/14/42and therefore consumes less expert time. This would
then allow more patients to have their resynchronisation
devices optimised and allow them to reap maximum
benefit from their devices.
A favourable result in this study could stimulate
worldwide change in practice by providing a new means
for improving patient’s symptomatic and physiological
outcomes using existing devices.
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